Log in | Join Free | china | japan | germany

6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)-

Request For Quotation
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Suppliers list
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Products Intro: Product Name:TW9
CAS:2614417-90-0
Purity:98% Package:1mg;5mg
Company Name: Cayman Chemical Company  
Tel: (800) 364-9897
Email: cayman@caymanchem.com
Products Intro: Product Name:TW9
CAS:2614417-90-0
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Basic information
Product Name:6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)-
Synonyms:6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)-
CAS:2614417-90-0
MF:C32H28ClN7O2S
MW:610.13
EINECS:
Product Categories:
Mol File:2614417-90-0.mol
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Structure
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Chemical Properties
density 1.44±0.1 g/cm3(Predicted)
solubility DMF: 20 mg/ml; DMSO: 10 mg/ml
form A crystalline solid
pka13.20±0.70(Predicted)
Safety Information
MSDS Information
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Usage And Synthesis
DescriptionTW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 μM, respectively).1 It is selective for BD2 over BD1 in BRD4 (IC50 = 0.72 μM) and for HDAC1 over HDAC2 (IC50 = 2.5 μM). TW9 (50 nM) induces apoptosis in, and inhibits proliferation of, MIA PaCa-2 pancreatic cancer cells. It induces cell cycle arrest at the G1 phase in HPAC pancreatic cancer cells when used at a concentration of 2 μM. TW9 acts synergistically with gemcitabine to reduce the viability of HPAC cells.
References1. Zhang, X., Zegar, T., Weiser, T., et al. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma Int. J. Cancer 147(10),2847-2861(2020).
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Preparation Products And Raw materials
Tag:6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)-(2614417-90-0) Related Product Information